Matt Kelly is Perspectum’s Chief Innovation Officer, overseeing clinical studies and collaborations to support our technology and explore novel indications. Matt is also responsible for the data-driven evaluation of Perspectum’s technology and IP management. Matt brings 20 years of experience in academic and industrial research in the biomedical sciences to Perspectum. Since completing his B.Sc. in Neuroscience at Manchester University and PhD in Pharmacology at De Novo Pharmaceuticals, a University of Cambridge spin-out, Matt has worked at the University of Oxford and Siemens Healthcare developing state-of-the-art technology for medical imaging and oncology. Matt has had over 25 patents granted and published 23 peer-reviewed journal articles.